Immunomedics is advancing the science of antibody-drug conjugate (ADC) technology with its next-generation ADC linker, designed to effectively balance directed delivery of an active therapeutic agent to the tumor site with manageable side effects to help transform the lives of people with hard-to-treat cancers.